CVS Health will not cover Amgen’s Neupogen in favor of Novartis biosimilar
CVS Health will no longer cover Thousand Oaks-based Amgen’s Neupogen on its standard drug plan in 2017, favoring the biosimilar Zarxio from Novartis. CVS, which is the second largest benefits manager behind Express Scripts and also owns the largest chain of drug stores in the U.S., said Aug. 2 it will choose biosimilar drugs over Read More →
FDA declines to approve Novartis biosimilar for Amgen’s Neulasta
The Food and Drug Administration has declined for now to approve a copycat version of Amgen’s blockbuster drug Neulasta. Reuters reported July 19 that the FDA sent a letter to Swiss pharmaceutical Novartis at the end of June saying it was declining to approve the drug for now. Neulasta, made by Thousand Oaks-based biotech giant Read More →
Amgen wins one, loses one in biosimilar battle
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen’s new drug for migraines shows promise
Thousand Oaks-based Amgen said a drug being developed in collaboration with Novartis showed promising results in providing relief for patients suffering from chronic migraines. The Phase 2 clinical trial met benchmarks for migraine reduction at two levels of dosage and with limited side effects. “Migraine is the sixth-leading cause of disability worldwide. Three to seven Read More →
Thousand Oaks’ Amgen just keeps chugging along
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Novartis biosimilar works as well as Amgen’s Neulasta
Swiss pharmaceutical Novartis announced Monday that a copycat version of Amgen’s Neulasta works just as well to prevent a condition that can lead to infection in women with breast cancer. Neulasta stimulates white blood cell production in the body, which helps the body fight cancer. Novartis’ new drug is part of a new class of Read More →
Amgen bipolar about biosimilars
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
